ANZMTG - Australia and New Zealand Melanoma Trials Group Home | Login
ANZMTG - Australia and New Zealand Melanoma Trials Group
 

LOGIN



Please enter your username and password.


Username

Password


  
ANZMTG
 

ANZMTG 01.10 - CARPETS

Oral kinase inhibitors such as vemurafenib are proving to be effective in up to 60% of malignant melanomas that are found to have a BRAF mutation. However drug resistance is emerging and many patients relapse, affirming the need for alternative treatments. Given the evidence for immune system involvement in the natural history and treatment of melanoma, research is being conducted to investigate the use of adoptive T-cell immunotherapy. This Phase I study is assessing the safety and immune effects of using retrovirally gene-modified autologous T cells in GD2 positive patients being treated with vemurafenib.
 
Study status - Open to recruitment 
ANZ Clinical Trials Registry # -  12613000198729

Principal Investigator's details:
Prof. Michael Brown
Royal Adelaide Hospital Cancer Centre
Email: michael.brown@health.sa.gov.au

ANZMTG coordinator details:
Anne Milton
Royal Adelaide Hospital Cancer Centre
Email: anne.milton@health.sa.gov.au
Phone: +61 8 8222 2702

Documents (PDF downloads):
       


Return to Previous Page